Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

Lawrence A Leiter, Gisle Langslet, Ujjwala Vijapurkar, Michael J Davies, William Canovatchel, Lawrence A Leiter, Gisle Langslet, Ujjwala Vijapurkar, Michael J Davies, William Canovatchel

Abstract

Introduction: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has demonstrated sustained improvements in glycemic control and body weight reductions with treatment for up to 104 weeks in a broad range of patients with type 2 diabetes mellitus (T2DM).

Methods: This was a post hoc analysis of individual patient data (N = 1450) from a randomized, double-blind, placebo-controlled, Phase 3 study comparing canagliflozin with glimepiride as add-on to metformin in patients with T2DM during a 52-week core period followed by a 52-week extension period. The number of patients who achieved a reduction from baseline in both HbA1c and body weight with canagliflozin 100 and 300 mg and glimepiride was assessed at Weeks 52 and 104. Safety was recorded as adverse events (AEs) during the study.

Results: Canagliflozin 100 and 300 mg provided durable glycemic improvements and body weight reductions compared with glimepiride over 104 weeks. At Week 52, the proportion of patients who achieved reductions in both HbA1c and body weight was 72.4% with canagliflozin 100 mg, 78.5% with canagliflozin 300 mg, and 26.8% with glimepiride; similar results were observed at Week 104 (65.5%, 71.1%, and 26.8% with canagliflozin 100 and 300 mg and glimepiride, respectively). The AE profile of canagliflozin was comparable to that observed in previous studies, with increased incidence of AEs related to the mechanism of SGLT2 inhibition (e.g., genital mycotic infections, urinary tract infections, and osmotic diuresis-related AEs) and a low risk of hypoglycemia.

Conclusion: More patients treated with canagliflozin experienced reductions in both HbA1c and body weight compared with glimepiride for up to 104 weeks. Canagliflozin was generally well tolerated in patients with T2DM when used in combination with metformin.

Clinical trial registration: ClinicalTrials.gov identifier, NCT00968812.

Funding: Janssen Research & Development, LLC.

Keywords: Body weight; Canagliflozin; Glimepiride; Glycated hemoglobin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus.

Figures

Fig. 1
Fig. 1
Change in both HbA1c and body weight with a CANA 100 mg and b CANA 300 mg versus GLIM at Week 52. CANA canagliflozin, GLIM glimepiride
Fig. 2
Fig. 2
Change in both HbA1c and body weight with a CANA 100 mg and b CANA 300 mg versus GLIM at Week 104. CANA canagliflozin, GLIM glimepiride

References

    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. doi: 10.2337/dc14-2441.
    1. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes Metab. 2008;10:1–7. doi: 10.1111/j.1463-1326.2008.00884.x.
    1. Gordon JP, Evans M, Puelles J, McEwan PC. Factors predictive of weight gain and implications for modeling in type 2 diabetes patients initiating metformin and sulfonylurea combination therapy. Diabetes Ther. 2015;6:495–507. doi: 10.1007/s13300-015-0134-y.
    1. Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28–43. doi: 10.1111/nyas.12852.
    1. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672. doi: 10.1111/j.1463-1326.2011.01406.x.
    1. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161. doi: 10.2337/dc12-2391.
    1. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950. doi: 10.1016/S0140-6736(13)60683-2.
    1. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis D, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–364. doi: 10.2337/dc13-2762.
    1. Einarson TR, Diels J, Garg M, et al. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab. 2014;16:492–499. doi: 10.1111/dom.12226.
    1. National Institutes of Health (NIH). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Evidence Report; NIH Publication No. 98-4083. 1998.
    1. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–2022. doi: 10.2337/dc11-0606.
    1. Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16:1111–1120. doi: 10.1111/dom.12327.
    1. Del Prato S, Nauck M, Durán-García S, Maffei L, Rohwedder K, Theuerkauf A, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581–590. doi: 10.1111/dom.12459.
    1. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700. doi: 10.1016/S2213-8587(14)70120-2.
    1. Rohwedder K, Nauck M, Durán-García S, et al. Combined HbA1c and weight reduction is achieved more frequently with add-on dapagliflozin than add-on glipizide in patients with type 2 diabetes inadequately controlled on metformin. Presented at: 73rd Scientific Sessions of the American Diabetes Association: Chicago; June 21–25, 2013.
    1. Cefalu WT, Stenlöf K, Leiter LA, Wilding JPH, Blonde L, Polidori D, et al. Effects of canagliflozin on body weight and body composition, and relation to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187. doi: 10.1007/s00125-015-3547-2.
    1. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–1486. doi: 10.2337/dc10-2415.
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.
    1. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial. Am Heart J. 2013;166:217–223. doi: 10.1016/j.ahj.2013.05.007.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit